Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers

Clinical Pharmacology and Therapeutics
K M WilliamsonJohn A Pieper

Abstract

Losartan is metabolized by CYP2C9 and CYP3A4 to an active metabolite, E3174, which has greater antihypertensive activity than the parent compound. Coadministered drugs that inhibit or induce metabolic processes may therefore alter the pharmacokinetics and pharmacologic response of losartan and E3174. Ten healthy volunteers were studied to assess the effects of CYP3A4 inhibition and nonspecific P450 enzyme induction on the pharmacokinetics of losartan and E3174. Subjects completed three 1-week phases separated by 6 days: 50 mg losartan every morning, losartan plus 500 mg erythromycin four times a day, and losartan plus 300 mg rifampin (INN, rifampicin) twice a day. On the eighth day of each phase, serial plasma concentrations of losartan and E3174 were obtained over 32 hours and steady-state pharmacokinetics were determined. Rifampin decreased the area under the concentration-time curve from time zero to 24 hours after the dose (AUC[0-24]) of losartan by 35% (349 +/- 246 versus 225 +/- 130; p = 0.0001) and decreased the AUC(0-24) of E3174 by 40% (1336 +/- 445 versus 792 +/- 302; p < 0.005). Losartan oral clearance was increased by 44% (p = 0.0001). The half-life values of both compounds were decreased by 50% (p < 0.005). In cont...Continue Reading

References

Jan 6, 1992·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·M MauriceP Maurel
Oct 1, 1987·Clinical Pharmacology and Therapeutics·L D HeimarkD A Goulart
Sep 15, 1984·Lancet·N J DanielsR K Schachter
Jan 1, 1995·Journal of Hepatology·H WietholtzS Matern
Aug 1, 1994·Pharmacogenetics·P B Watkins
Mar 1, 1993·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·K A Bachmann, L Jauregui
Apr 30, 1996·Proceedings of the National Academy of Sciences of the United States of America·E G SchuetzJ D Schuetz
Mar 1, 1996·Clinical Pharmacology and Therapeutics·M R GoldbergJ B McCrea
Jul 1, 1996·Pharmaceutical Research·A Tsuji, I Tamai

❮ Previous
Next ❯

Citations

Jul 15, 1998·British Journal of Clinical Pharmacology·J O Miners, D J Birkett
Jan 3, 2001·British Journal of Clinical Pharmacology·M NiemiP J Neuvonen
Jan 21, 2010·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Ritu RanaJoyce A Goldstein
Mar 4, 2008·Molecular Pharmacology·Melissa A KramerRonald N Hines
Jul 1, 2005·Future Cardiology·Sanne de VogelVasilios Papademetriou
Feb 18, 2003·American Journal of Respiratory and Critical Care Medicine·Henry M BlumbergUNKNOWN American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society
Feb 16, 2005·Expert Opinion on Drug Safety·Steffen BöhlerWilhelm Kirch
Jan 29, 2005·British Journal of Clinical Pharmacology·H GlaeserM F Fromm
Feb 18, 2003·Pharmacotherapy·J Herbert Patterson
May 22, 2009·The Annals of Pharmacotherapy·Guo WangHong-Hao Zhou
Jan 11, 2003·Journal of Clinical Pharmacology·Craig R LeeJoyce A Goldstein
Apr 10, 1999·Journal of Clinical Pharmacology·A M MeadowcroftJ A Pieper
Jul 12, 2008·Archives of Toxicology·Olavi PelkonenHannu Raunio
Aug 19, 2010·British Journal of Clinical Pharmacology·Atholl JohnstonGeorge S Stergiou
May 23, 2001·Clinical Pharmacokinetics·C D Scripture, J A Pieper
Jul 17, 2003·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Thomas Unger, Elena Kaschina
Sep 24, 2005·Clinical Pharmacokinetics·Helen C SwaislandMartin J Wild
Jul 21, 2005·Clinical Pharmacokinetics·Domenic A SicaSiddhartha Ghosh
Mar 13, 2002·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·W W Yew
Jul 29, 2003·Clinical Pharmacokinetics·Mikko NiemiKari T Kivistö
May 1, 2008·Drug Metabolism and Pharmacokinetics·Mariko KobayashiKazuyuki Ueno
Dec 31, 2008·American Journal of Therapeutics·Judy W M ChengWilbert S Aronow
Jul 17, 2014·European Journal of Clinical Pharmacology·Ben D SnyderMatthew P Doogue
Sep 8, 2011·The Journal of Clinical Hypertension·Addison A TaylorShawna Nesbitt
Sep 14, 2006·Pharmacological Reviews·Sharon J Gardiner, Evan J Begg
Nov 6, 2012·Expert Review of Clinical Pharmacology·Janne Hukkanen
Jul 17, 2009·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Z LiH-H Zhou
Nov 30, 2018·Current Drug Metabolism·Panjasaram Naidoo, Manoranjenni Chetty
Mar 29, 2003·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Toshio OgiharaHiroshi Mikami
Aug 2, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Magang ShouGary L Skiles
Nov 6, 2003·The Journal of Pharmacology and Experimental Therapeutics·Yuping ChenJoyce A Goldstein
Jan 30, 2021·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Hang-Xing HuangYong Lai
Oct 29, 2020·Archives of Toxicology·Jukka HakkolaOlavi Pelkonen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.